CD4 and myeloid sarcoma: Th1 (IFN-γ) and Th17 (IL-17) responses and proliferative responses of CD4+ and CD8+ T cells were reduced in MS patients treated with rituximab compared with baseline these modifications were suggested to be mediated by a reduced production of the pro-inflammatory cytokines lymphotoxin and TNF-α by the repopulated B cells (75).